RSS   Newsletter   Contact   Advertise with us
Post Online Media

Valeant appoints Paul Herendeen as EVP, finance and CFO

ValeantValeant Pharmaceuticals International, Inc. announced that Paul S. Herendeen has been appointed EVP, finance and will take over the chief financial officer role.
Prior to joining Valeant, Mr. Herendeen served as Executive Vice President and Chief Financial Officer of Zoetis Inc. for two years.

From 2005 to 2013 and from 1998 to 2001, Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company.

He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe, a privately held health care company, where he served as CFO from 2001 until 2005.

Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies.

He also spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation, and as a senior auditor with Arthur Andersen & Company.

Mr. Herendeen earned a Master of Business Administration (MBA) from the University of Virginia's Darden School of Business, and holds a bachelor's degree in Business Administration from Boston College.

He takes over CFO role from Robert L. Rosiello who will remain at Valeant as Executive Vice President, Corporate Development and Strategy.




We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy